<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7140116\results\search\drugs\results.xml">
  <result pre="for the improvement of current antimetabolite-based treatments. SAMHD1 antimetabolite CDK4/6" exact="pemetrexed" post="HIV cancer 1. Introduction Sterile alpha motif and histidine-aspartic"/>
  <result pre="inactivation of a number of different nucleoside analogues [30,31], including" exact="cytarabine" post="(Cytosar-U®,Ara-C), a first line therapeutic agent for acute myelogenous"/>
  <result pre="degradation either enhanced (cladribine, clofarabine, and nelarabine) or decreased (capecitabine," exact="floxuridine" post="and fluorouracil) the potency of the nucleoside analogues tested"/>
  <result pre="degradation dramatically impaired the efficacy of anti-folate inhibitors such as" exact="pemetrexed" post="and methotrexate (Figure 2B). Calculation of 50% effective concentrations"/>
  <result pre="impaired the efficacy of anti-folate inhibitors such as pemetrexed and" exact="methotrexate" post="(Figure 2B). Calculation of 50% effective concentrations (EC50) of"/>
  <result pre="SAMHD1 also affected the efficacy of anti-folate drugs such as" exact="pemetrexed" post="and methotrexate (Table 1). 2.2. SAMHD1 Is Required for"/>
  <result pre="affected the efficacy of anti-folate drugs such as pemetrexed and" exact="methotrexate" post="(Table 1). 2.2. SAMHD1 Is Required for Antiviral Activity"/>
  <result pre="[14]. The antiviral activity of the highly selective CDK4/6 inhibitor" exact="palbociclib" post="is dependent on SAMHD1 expression [14,19] (Figure 3A). Thus,"/>
  <result pre="SAMHD1. The three agents were tested at the concentration where" exact="palbociclib" post="showed the highest efficacy in cell culture (1 μM,"/>
  <result pre="3B). Interestingly, similar results were obtained when the multi-kinase inhibitor" exact="midostaurin" post="was evaluated (Figure S1A), suggesting that activity of multiple"/>
  <result pre="SAMHD1 expression and phosphorylation was measured by Western blot. Both" exact="palbociclib" post="and midostaurin blocked SAMHD1 phosphorylation, whereas SAMHD1 protein expression"/>
  <result pre="and phosphorylation was measured by Western blot. Both palbociclib and" exact="midostaurin" post="blocked SAMHD1 phosphorylation, whereas SAMHD1 protein expression was not"/>
  <result pre="decreased expression of Rb, a substrate of CDK6, suggesting that" exact="palbociclib" post="and midostaurin also affect CDK6-mediated CDK2 phosphorylation of SAMHD1"/>
  <result pre="of Rb, a substrate of CDK6, suggesting that palbociclib and" exact="midostaurin" post="also affect CDK6-mediated CDK2 phosphorylation of SAMHD1 (Figure 3C,"/>
  <result pre="inhibition of its phosphorylation. Thus, we evaluated the capacity of" exact="palbociclib" post="to modify the activity of antimetabolites. Antiviral activity of"/>
  <result pre="palbociclib to modify the activity of antimetabolites. Antiviral activity of" exact="pemetrexed" post="and fluorouracil were evaluated alone or in combination with"/>
  <result pre="modify the activity of antimetabolites. Antiviral activity of pemetrexed and" exact="fluorouracil" post="were evaluated alone or in combination with palbociclib in"/>
  <result pre="pemetrexed and fluorouracil were evaluated alone or in combination with" exact="palbociclib" post="in primary macrophages. Pemetrexed inhibited HIV-1 replication in a"/>
  <result pre="(EC50 = 0.1 µM, Figure 4A, black line). Combination of" exact="pemetrexed" post="with increasing concentrations of palbociclib (EC50 = 0.12 µM)"/>
  <result pre="4A, black line). Combination of pemetrexed with increasing concentrations of" exact="palbociclib" post="(EC50 = 0.12 µM) enhanced the antiviral potency of"/>
  <result pre="combination index (CI) indicated strong synergy (CI ≤ 0.041 for" exact="palbociclib" post="at 0.04 µM combined with different concentrations of pemetrexed,"/>
  <result pre="µM combined with different concentrations of pemetrexed, Table 2). Interestingly," exact="pemetrexed" post="and palbociclib activity, as well as the synergistic effect"/>
  <result pre="with different concentrations of pemetrexed, Table 2). Interestingly, pemetrexed and" exact="palbociclib" post="activity, as well as the synergistic effect observed in"/>
  <result pre="of SAMHD1, (Figure 4A,B, right panels). Furthermore, the combination of" exact="pemetrexed" post="with the multi-kinase inhibitor midostaurin (EC50 = 0.62 µM)"/>
  <result pre="panels). Furthermore, the combination of pemetrexed with the multi-kinase inhibitor" exact="midostaurin" post="(EC50 = 0.62 µM) also showed a highly synergistic"/>
  <result pre="panels). On the other hand, combination of the nucleoside analogue" exact="fluorouracil" post="or the multikinase inhibitor midostaurin with palbociclib showed more"/>
  <result pre="combination of the nucleoside analogue fluorouracil or the multikinase inhibitor" exact="midostaurin" post="with palbociclib showed more limited effects, i.e., palbociclib partially"/>
  <result pre="the nucleoside analogue fluorouracil or the multikinase inhibitor midostaurin with" exact="palbociclib" post="showed more limited effects, i.e., palbociclib partially enhanced the"/>
  <result pre="multikinase inhibitor midostaurin with palbociclib showed more limited effects, i.e.," exact="palbociclib" post="partially enhanced the antiviral potency of fluorouracil or midostaurin"/>
  <result pre="limited effects, i.e., palbociclib partially enhanced the antiviral potency of" exact="fluorouracil" post="or midostaurin in the presence of SAMHD1 (Figure S2)."/>
  <result pre="i.e., palbociclib partially enhanced the antiviral potency of fluorouracil or" exact="midostaurin" post="in the presence of SAMHD1 (Figure S2). Combination index"/>
  <result pre="cell growth, thus we evaluated cytotoxic efficacy of the antimetabolites" exact="pemetrexed" post="and fluorouracil in combination with the CDK4/6 inhibitor palbociblib"/>
  <result pre="thus we evaluated cytotoxic efficacy of the antimetabolites pemetrexed and" exact="fluorouracil" post="in combination with the CDK4/6 inhibitor palbociblib in the"/>
  <result pre="showed significant differences between them (Table S1). The combination of" exact="pemetrexed" post="with palbociclib enhanced the cytotoxicity of the antimetabolite in"/>
  <result pre="differences between them (Table S1). The combination of pemetrexed with" exact="palbociclib" post="enhanced the cytotoxicity of the antimetabolite in all cell"/>
  <result pre="when antiviral efficacy was measured (Table 3). The combination of" exact="fluorouracil" post="with palbociclib enhanced fluorouracil potency in TZM-bl and T47D"/>
  <result pre="efficacy was measured (Table 3). The combination of fluorouracil with" exact="palbociclib" post="enhanced fluorouracil potency in TZM-bl and T47D cells but"/>
  <result pre="measured (Table 3). The combination of fluorouracil with palbociclib enhanced" exact="fluorouracil" post="potency in TZM-bl and T47D cells but not in"/>
  <result pre="inhibitor palbociclib, protein expression in primary macrophages treated with pemetrexed," exact="fluorouracil" post="and palbociclib, alone or in combination was evaluated (Figure"/>
  <result pre="alone or in combination was evaluated (Figure 6A). As expected," exact="palbociclib" post="alone inhibited phosphorylation of pRb and SAMHD1, therefore activating"/>
  <result pre="triphosphohydrolase function and subsequently reducing the intracellular dNTP pool. Interestingly," exact="pemetrexed" post="and fluorouracil treatment resulted in different effects, i.e., while"/>
  <result pre="and subsequently reducing the intracellular dNTP pool. Interestingly, pemetrexed and" exact="fluorouracil" post="treatment resulted in different effects, i.e., while fluorouracil acts"/>
  <result pre="pemetrexed and fluorouracil treatment resulted in different effects, i.e., while" exact="fluorouracil" post="acts similarly to palbociclib, pemetrexed did not decrease the"/>
  <result pre="in different effects, i.e., while fluorouracil acts similarly to palbociclib," exact="pemetrexed" post="did not decrease the phosphorylation of pRb and SAMHD1."/>
  <result pre="did not decrease the phosphorylation of pRb and SAMHD1. Although" exact="pemetrexed" post="activity is dependent on SAMHD1, its mechanisms of action"/>
  <result pre="pemetrexed–palbociclib drug combination compared to fluorouracil–palbociblib. Thus, antifolates such as" exact="pemetrexed" post="inhibit the dNTP pool by a mechanism not directly"/>
  <result pre="other hand, when two compounds directly affecting SAMHD1 phosphorylation (i.e.," exact="fluorouracil" post="and palbociclib) are combined, the synergic effect is less"/>
  <result pre="analogues but also anti-folate drugs. Interestingly, antifolate drugs such as" exact="pemetrexed" post="or methotrexate showed increased potency in SAMHD1-expressing cells, whereas"/>
  <result pre="also anti-folate drugs. Interestingly, antifolate drugs such as pemetrexed or" exact="methotrexate" post="showed increased potency in SAMHD1-expressing cells, whereas nucleoside analogues"/>
  <result pre="(AraC and clofarabine) and other types of hematological cancers like" exact="nelarabine" post="for T-lymphoblastic lymphoma, cladribine used in the treatment of"/>
  <result pre="other types of hematological cancers like nelarabine for T-lymphoblastic lymphoma," exact="cladribine" post="used in the treatment of hairy cell leukemia and"/>
  <result pre="serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA), penicillin and" exact="streptomycin" post="(Thermo Fisher Scientific, Waltham, MA, USA) and differentiated to"/>
  <result pre="technique as described elsewhere (22). 4.2. Drugs 33-Azido-3-deoxythymidine (zidovudine, AZT)," exact="nevirapine" post="(NVP), 1-beta-D-Arabinofuranosylcytosine (AraC), 9-beta-D-Arabinofuranosyl-2-fluoroadenine (fludarabine), 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine (nelarabine), 2-Chloro-2′-deoxyadenosine (cladribine),"/>
  <result pre="2-Chloro-2′-deoxyadenosine (cladribine), 2-chloro-9-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (clofarabine), 2′,2′-Difluorodeoxycytidine (gemcitabine), 5-Fluoro-2-desoxyuridine (floxuridine), 5-Fluoropyrimidine-2,4-dione (fluorouracil)," exact="pemetrexed" post="and 4′-N-benzoylstaurosporine (midostaurin) were purchased from Sigma-Aldrich (Madrid, Spain)."/>
  <result pre="online at https://www.mdpi.com/2072-6694/12/3/713/s1, Figure S1: Efficacy of the multi-kinase inhibitor" exact="midostaurin" post="depends on SAMHD1 expression, Figure S2: Relative effect of"/>
  <result pre="Cycle2017161029103810.1080/15384101.2017.131440728436707 28.HeroldN.RuddS.G.LjungbladL.SanjivK.MyrbergI.H.PaulinC.B.J.HeshmatiY.HagenkortA.KutznerJ.PageB.D.G.et al.Targeting SAMHD1 with the Vpx protein to improve" exact="cytarabine" post="therapy for hematological malignanciesNat. Med.20172325626310.1038/nm.426528067901 29.SchneiderC.OellerichT.BaldaufH.-M.SchwarzS.-M.ThomasD.FlickR.BohnenbergerH.KaderaliL.StegmannL.CremerA.et al.SAMHD1 is a"/>
  <result pre="for hematological malignanciesNat. Med.20172325626310.1038/nm.426528067901 29.SchneiderC.OellerichT.BaldaufH.-M.SchwarzS.-M.ThomasD.FlickR.BohnenbergerH.KaderaliL.StegmannL.CremerA.et al.SAMHD1 is a biomarker for" exact="cytarabine" post="response and a therapeutic target in acute myeloid leukemiaNat."/>
  <result pre="and drug resistance activities of SAMHD1Exp. Hematol.201752323910.1016/j.exphem.2017.05.00128502830 36.JoergerM.OmlinA.CernyT.FrühM.The role of" exact="pemetrexed" post="in advanced non small-cell lung cancer: Special focus on"/>
  <result pre="of untreated MDMs (no drug, ND) or macrophages treated with" exact="palbociclib" post="at the indicated doses. Membranes were blotted with an"/>
  <result pre="antiviral activity. Inhibition of HIV infection with increasing doses of" exact="palbociclib" post="and pemetrexed was measured. Percentage of GFP+ cells relative"/>
  <result pre="Inhibition of HIV infection with increasing doses of palbociclib and" exact="pemetrexed" post="was measured. Percentage of GFP+ cells relative to the"/>
  <result pre="duplicate is shown. (B) As in (A), relative effect of" exact="pemetrexed" post="alone (white bars) or in combination with a fixed"/>
  <result pre="(white bars) or in combination with a fixed dose of" exact="palbociclib" post="0.04 µM (black bars), in the presence (left panel)"/>
  <result pre="antiviral activity. Inhibition of HIV infection with increasing doses of" exact="midostaurin" post="and pemetrexed was measured. Percentage of GFP+ cells relative"/>
  <result pre="Inhibition of HIV infection with increasing doses of midostaurin and" exact="pemetrexed" post="was measured. Percentage of GFP+ cells relative to the"/>
  <result pre="duplicate is shown. (D) As in (C), relative effect of" exact="pemetrexed" post="(PTX) alone (white bars) or in combination with a"/>
  <result pre="(white bars) or in combination with a fixed dose of" exact="midostaurin" post="0.2 µM (black bars), in the presence (left panel)"/>
  <result pre="and MDA-MB-468 cell lines, respectively. Left panels, cytotoxic activity of" exact="palbociclib" post="alone (5 µM, white bars), pemetrexed alone (black bars"/>
  <result pre="panels, cytotoxic activity of palbociclib alone (5 µM, white bars)," exact="pemetrexed" post="alone (black bars at 0.2, 1 or 0.04 µM"/>
  <result pre="the same concentration (grey bars). Right panels, cytotoxic activity of" exact="palbociclib" post="alone (5 µM, white bars), fluorouracil alone (5 µM,"/>
  <result pre="panels, cytotoxic activity of palbociclib alone (5 µM, white bars)," exact="fluorouracil" post="alone (5 µM, black bars) or the combination of"/>
  <result pre="for drug synergy. (A) Protein expression in MDMs treated with" exact="palbociclib" post="(PD) at 1 µM, pemetrexed (PTX) and fluorouracil (FU),"/>
  <result pre="expression in MDMs treated with palbociclib (PD) at 1 µM," exact="pemetrexed" post="(PTX) and fluorouracil (FU), both at 5µM and the"/>
  <result pre="treated with palbociclib (PD) at 1 µM, pemetrexed (PTX) and" exact="fluorouracil" post="(FU), both at 5µM and the corresponding drug combinations"/>
  <result pre="model of drug interactions. Antimetabolites affecting dNTP synthesis such as" exact="pemetrexed" post="inhibit dNTP pool by a mechanism not directly affecting"/>
  <result pre="and thus synergy with anticancer drugs affecting SAMHD1 phosphorylation as" exact="palbociclib" post="is higher compared to compounds also targeting SAMHD1 function"/>
  <result pre="of antimetabolites (AraC, fludarabine, nelarabine, cladribine, clofarabine, gemcitabine, floxuridine, fluorouracil," exact="pemetrexed" post="and methotrexate) and antiretrovirals (AZT and NVP) in macrophages"/>
  <result pre="or inversely (+/-). cancers-12-00713-t002_Table 2Table 2 Combination index values for" exact="pemetrexed" post="and fluorouracil combinations with palbociclib and midostaurin. Macrophages were"/>
  <result pre="(+/-). cancers-12-00713-t002_Table 2Table 2 Combination index values for pemetrexed and" exact="fluorouracil" post="combinations with palbociclib and midostaurin. Macrophages were treated with"/>
  <result pre="2 Combination index values for pemetrexed and fluorouracil combinations with" exact="palbociclib" post="and midostaurin. Macrophages were treated with the different at"/>
  <result pre="different at indicated concentrations in combination with 0.04 µM of" exact="palbociclib" post="or 0.2 µM of midostaurin and infected with HIV-1"/>
  <result pre="combination with 0.04 µM of palbociclib or 0.2 µM of" exact="midostaurin" post="and infected with HIV-1 for 48 h. Drug efficacy was"/>
  <result pre="= 1, additive. cancers-12-00713-t003_Table 3Table 3 Combination index values for" exact="pemetrexed" post="and fluorouracil combinations with palbociclib. TZM-bl, MDA-MB-468 and T47D"/>
  <result pre="additive. cancers-12-00713-t003_Table 3Table 3 Combination index values for pemetrexed and" exact="fluorouracil" post="combinations with palbociclib. TZM-bl, MDA-MB-468 and T47D cells were"/>
  <result pre="MDA-MB-468 and T47D cells were treated with indicated concentrations of" exact="pemetrexed" post="or fluorouracil in combination with 5 µM of palbociclib."/>
  <result pre="T47D cells were treated with indicated concentrations of pemetrexed or" exact="fluorouracil" post="in combination with 5 µM of palbociclib. Cytotoxic effect"/>
 </snippets>
</snippetsTree>
